Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.

Kang KH, Grubb W, Sawlani K, Gibson MK, Hoimes CJ, Rogers LR, Lavertu P, Yao M.

Am J Otolaryngol. 2018 Jun 5. pii: S0196-0709(18)30361-2. doi: 10.1016/j.amjoto.2018.06.003. [Epub ahead of print]

PMID:
29903623
2.

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.

Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P.

Urol Oncol. 2018 Mar 29. pii: S1078-1439(18)30075-9. doi: 10.1016/j.urolonc.2018.02.018. [Epub ahead of print] Review.

PMID:
29606341
3.

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P.

Cancer. 2018 May 15;124(10):2115-2124. doi: 10.1002/cncr.31314. Epub 2018 Mar 8.

PMID:
29517810
4.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM.

JAMA Oncol. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.

PMID:
28817753
5.

Editorial Comment.

Hoimes CJ, Madabhushi A.

Urology. 2016 Feb;88:132-3. doi: 10.1016/j.urology.2015.09.043. No abstract available.

PMID:
26964790
6.

Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort.

Kiechle JE, Abouassaly R, Gross CP, Dong S, Cherullo EE, Zhu H, Trinh QD, Sun M, Meropol NJ, Hoimes CJ, Ialacci S, Kim SP.

Urology. 2016 Apr;90:69-74. doi: 10.1016/j.urology.2015.10.035. Epub 2015 Dec 24.

PMID:
26724412
7.

The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles.

Deng Y, Saucier-Sawyer JK, Hoimes CJ, Zhang J, Seo YE, Andrejecsk JW, Saltzman WM.

Biomaterials. 2014 Aug;35(24):6595-602. doi: 10.1016/j.biomaterials.2014.04.038. Epub 2014 May 9.

8.

Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.

Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, Weiss RM.

Nanomedicine. 2013 Nov;9(8):1124-34. doi: 10.1016/j.nano.2013.05.017. Epub 2013 Jun 11.

9.

Redefining hormone resistance in prostate cancer.

Hoimes CJ, Kelly WK.

Ther Adv Med Oncol. 2010 Mar 1;2(2):107-123.

10.

Hodgkin's lymphoma of the breast.

Hoimes CJ, Selbst MK, Shafi NQ, Rose MG, Rosado MF.

J Clin Oncol. 2010 Jan 10;28(2):e11-3. doi: 10.1200/JCO.2009.23.1613. Epub 2009 Nov 2. No abstract available.

PMID:
19884545
11.

TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortality.

Hoimes CJ, Kelly WK.

Update Cancer Ther. 2009;3(4):157-159. No abstract available.

13.

Therapeutic tools in pancreatic cancer.

Hoimes CJ, Strimpakos AS, Saif MW.

JOP. 2009 Mar 9;10(2):118-22.

Supplemental Content

Loading ...
Support Center